我们对 SRC 家族酪氨酸激酶参与癌症的大部分了解源于对典型 SRC 癌基因的研究。然而，新兴研究揭示了 YES 信号在致癌转化、肿瘤生长、转移进展和对各种癌症治疗的耐药性中的重要作用。临床证据表明，YES 的表达或活性失调在人类癌症中经常发生，并与不利的结果相关。这些发现为在某些癌症亚型中专门针对 YES 提供了令人信服的理由。在这里，我们回顾了 YES 在癌症中的关键作用，并讨论了将临床前观察结果转化为有效的 YES 靶向疗法所面临的挑战。© 2023。作者，获得 Springer Nature Limited 的独家许可。

Most of our understanding regarding the involvement of SRC-family tyrosine kinases in cancer has stemmed from studies focused on the prototypical SRC oncogene. However, emerging research has shed light on the important role of YES signaling in oncogenic transformation, tumor growth, metastatic progression, and resistance to various cancer therapies. Clinical evidence indicates that dysregulated expression or activity of YES is a frequent occurrence in human cancers and is associated with unfavorable outcomes. These findings provide a compelling rationale for specifically targeting YES in certain cancer subtypes. Here, we review the crucial role of YES in cancer and discuss the challenges associated with translating preclinical observations into effective YES-targeted therapies.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.